It has been shown in multicenter randomized trials to decrease the number of apheresis procedures required to achieve a minimum dose of CD34+ cells/kg necessary to proceed with transplant for patients with MM and NHL. The gene discussed is CD34; the disease is non-Hodgkin lymphoma.